EARLY BIRD REGISTRATION ENDS SEPTEMBER 1!
![shutterstock_2658171737 [Converted]_Smaller.jpg](https://static.wixstatic.com/media/dcb143_8063f21dfa5b4fe6890ff40ca69c3d51~mv2.jpg/v1/fill/w_147,h_49,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_avif,quality_auto/dcb143_8063f21dfa5b4fe6890ff40ca69c3d51~mv2.jpg)
Member Spotlight
Maureen A. Moriarty, DNP, ANP-BC, FAHS, FAANP
Maureen A. Moriarty is an adult nurse practitioner and nationally recognized headache specialist who cares for patients with migraine, cluster headache, tension-type headache, post-traumatic headache, and atypical facial pain. She is the founder of Moriarty Associates, a Comprehensive Headache Center, and previously cared for headache patients at MedStar Georgetown University Hospital. Dr. Moriarty also serves as an Associate Professor at Marymount University, where she supports graduate nursing education and teaches FNP and DNP students. Through lectures, publications, multimedia presentations, and clinical training, she is dedicated to advancing headache education for healthcare professionals and the broader community.
.png)
INDUSTRY NEWS
Will recent FDA approval of a novel
nonopioid analgesic be a game changer?
Physician's Weekly
The Food and Drug Administration recently approved Journavx, a first-in-class oral, nonopioid, highly selective sodium channel blocker indicated as a treatment for adults with moderate to severe acute pain. Clinical data revealed that this agent is an effective, well-tolerated medicine without evidence of addictive potential, indicated for use with all types of moderate to sever acute pain.
